• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Roxadustat for Renal Anemia in ESRD from PKD Patients: Is It Safe Enough?

作者信息

Liu Fei, Wang Jingjing, Ye Qing, Fu Haidong, Mao Jianhua

机构信息

Department of Nephrology, Children's Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Hangzhou, China.

Department of Clinical Laboratory, Children's Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

J Am Soc Nephrol. 2021 Apr;32(4):1005. doi: 10.1681/ASN.2020111664. Epub 2021 Mar 1.

DOI:10.1681/ASN.2020111664
PMID:33649100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8017543/
Abstract
摘要

相似文献

1
Roxadustat for Renal Anemia in ESRD from PKD Patients: Is It Safe Enough?罗沙司他用于多囊肾病患者终末期肾病的肾性贫血：它足够安全吗？
J Am Soc Nephrol. 2021 Apr;32(4):1005. doi: 10.1681/ASN.2020111664. Epub 2021 Mar 1.
2
Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study.罗沙司他与促红细胞生成素治疗慢性肾脏病患者肾性贫血的疗效比较：一项回顾性研究
Transl Androl Urol. 2022 Nov;11(11):1568-1576. doi: 10.21037/tau-22-709.
3
Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival.肾移植等待名单上患者的多囊肾病：血细胞比容和生存率的趋势
BMC Nephrol. 2002 Aug 23;3:7. doi: 10.1186/1471-2369-3-7.
4
Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report.罗沙司他用于治疗一名终末期肾病癌症患者的贫血：病例报告。
World J Clin Cases. 2022 Jul 6;10(19):6587-6594. doi: 10.12998/wjcc.v10.i19.6587.
5
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.肾功能和透析对罗沙司他（一种口服低氧诱导因子脯氨酰羟化酶抑制剂）的药代动力学和药效学的影响。
Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):141-153. doi: 10.1007/s13318-020-00658-w.
6
Clinical characteristics of polycystic kidney disease with end-stage renal disease. The Kanazawa Renal Disease Study Group.终末期肾病型多囊肾病的临床特征。金泽肾病研究小组。
Clin Nephrol. 1998 Aug;50(2):113-7.
7
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.罗沙司他（FG-4592）治疗维持性血液透析患者贫血的 2 期随机、6-19 周、开放标签、活性对照、剂量范围、安全性和探索性疗效研究：与促红细胞生成素α的比较
Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2.
8
Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他治疗非透析依赖性慢性肾脏病肾性贫血的有效性：一项系统评价和荟萃分析
Ann Transl Med. 2019 Dec;7(23):720. doi: 10.21037/atm.2019.12.18.
9
Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.罗沙司他治疗慢性肾脏病患者贫血的疗效：一项荟萃分析。
Aging (Albany NY). 2021 Jun 11;13(13):17914-17929. doi: 10.18632/aging.203143.
10
Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study.罗沙司他在透析依赖型肾性贫血患者中的安全性和有效性：一项基于医院的队列研究。
Cureus. 2022 Apr 23;14(4):e24427. doi: 10.7759/cureus.24427. eCollection 2022 Apr.

引用本文的文献

1
A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.一种新的慢性肾脏病贫血治疗管理方案：罗沙司他的应用。
J Nephrol. 2024 May;37(4):1107-1119. doi: 10.1007/s40620-023-01849-9. Epub 2024 Jan 8.
2
Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms PI3K signaling.罗沙司他（FG-4592）减轻了脂多糖诱导的类似抑郁症状的PI3K信号传导。
Front Mol Neurosci. 2023 Mar 15;16:1048985. doi: 10.3389/fnmol.2023.1048985. eCollection 2023.
3
Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications.罗沙司他，一种对糖尿病相关并发症具有潜在治疗潜力的低氧诱导因子脯氨酰羟化酶抑制剂。
Front Pharmacol. 2023 Feb 10;14:1088288. doi: 10.3389/fphar.2023.1088288. eCollection 2023.
4
Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.罗沙司他治疗慢性肾脏病患者贫血的感染风险：一项系统评价、荟萃分析及试验序贯分析
Front Pharmacol. 2022 Sep 16;13:967532. doi: 10.3389/fphar.2022.967532. eCollection 2022.
5
Roxadustat: Not just for anemia.罗沙司他：不止用于贫血。
Front Pharmacol. 2022 Aug 29;13:971795. doi: 10.3389/fphar.2022.971795. eCollection 2022.
6
Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.缺氧诱导因子稳定剂治疗慢性肾脏病贫血。
Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
7
Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction.多囊肾病中钠-葡萄糖协同转运蛋白抑制作用：事实还是虚构
Clin Kidney J. 2022 Jan 31;15(7):1275-1283. doi: 10.1093/ckj/sfac029. eCollection 2022 Jul.